NEW YORK (
) hit a new 52-week high Tuesday as it is currently trading at $13.09, above its previous 52-week high of $13 with 765,990 shares traded as of 10:30 a.m. ET. Average volume has been one million shares over the past 30 days.
Spectrum has a market cap of $698.6 million and is part of the
industry. Shares are up 87% year to date as of the close of trading on Monday.
Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company, primarily focuses on oncology and hematology. The company engages in acquiring, developing, and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. The company has a P/E ratio of 15.4, below the average drugs industry P/E ratio of 15.6 and below the S&P 500 P/E ratio of 17.7.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Spectrum as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full
52-week high stocks
or get investment ideas from our